AC   CVCL_1K17
DR   FCS-free; 212-28-432-1-6
DR   FCS-free; 212-28-432-1-16-12
DR   Wikidata; Q54938373
RX   DOI=10.4172/2157-7560.1000345;
RX   Patent=US8716016;
RX   PubMed=18524432;
RX   PubMed=21911025;
RX   PubMed=25903999;
CC   Group: Bird cell line.
CC   Group: Patented cell line.
CC   Group: Serum/protein free medium cell line.
CC   Group: Vaccine production cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8565.
CC   Transformant: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
CC   Derived from site: In situ; Embryo; UBERON=UBERON_0000922.
CC   Cell type: Fibroblast; CL=CL_0000057.
OX   NCBI_TaxID=9031; ! Gallus gallus (Chicken)
HI   CVCL_1K16 ! PBS-1
SX   Sex unspecified
AG   11FD
CA   Transformed cell line
DT   Created: 08-07-15; Last updated: 29-06-23; Version: 14
RX   DOI=10.4172/2157-7560.1000345;
RA   Sporer K.R.B., Carter J.L., Coussens P.M.;
RT   "The PBS-12SF cell line: development of an alternative cell line for
RT   influenza vaccine production.";
RL   J. Vaccines Vaccin. 7:345-345(2016).
RX   Patent=US8716016;
RA   Coussens P.M., Smith K.A., Weber P.S.D.;
RT   "Immortal avian cell line and methods of use.";
RL   Patent number US8716016, 06-May-2014.
RX   PubMed=18524432; DOI=10.1016/j.vaccine.2008.04.048;
RA   Smith K.A., Colvin C.J., Weber P.S.D., Spatz S.J., Coussens P.M.;
RT   "High titer growth of human and avian influenza viruses in an
RT   immortalized chick embryo cell line without the need for exogenous
RT   proteases.";
RL   Vaccine 26:3778-3782(2008).
RX   PubMed=21911025; DOI=10.1016/j.vaccine.2011.08.122;
RA   Coussens P.M., Smith K.A., Weber P.S.D., Colvin C.J.;
RT   "Immortalized chick embryo cell line adapted to serum-free growth
RT   conditions and capable of replicating human and reassortant H5N1
RT   influenza strains for vaccine production.";
RL   Vaccine 29:8661-8668(2011).
RX   PubMed=25903999; DOI=10.1002/biot.201400388;
RA   Genzel Y.;
RT   "Designing cell lines for viral vaccine production: where do we
RT   stand?";
RL   Biotechnol. J. 10:728-740(2015).